Status:
RECRUITING
A Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer Patients
Lead Sponsor:
FangYi
Conditions:
Breast Neoplasms
Quality of Life (QOL)
Eligibility:
FEMALE
18+ years
Brief Summary
This study, called PERSEVERE, examines how local treatment for early breast cancer affects people's health and daily lives over time. People who join the study will have early-stage breast cancer and...
Detailed Description
PERSEVERE is a prospective, multi-modal cohort study designed to evaluate treatment-related toxicities and quality of life in people with stage I-III early breast cancer receiving local therapy in Chi...
Eligibility Criteria
Inclusion Criteria:
- Women aged 18 years or older
- Diagnosed with stage I, II, or III invasive breast cancer confirmed by pathology or cytology
- No signs of metastatic disease (cancer that has spread to other parts of the body)
- Scheduled to receive local treatment, including:
Surgery
And/or neoadjuvant or adjuvant therapy such as chemotherapy, radiation, hormone therapy, or targeted therapy
- Willing and able to complete health questionnaires and attend follow-up visits
- Has given written informed consent to join the study
Exclusion Criteria:
- Have metastatic breast cancer or local recurrence
- Have already received curative treatment (surgery, chemo, etc.) for the current breast cancer before joining the study
- Are currently pregnant or breastfeeding
- Have a history of another cancer within the past 5 years (except for non-melanoma skin cancer or in-situ cervical cancer)
- Are unable to participate in the study due to mental, physical, or legal reasons (for example, under legal guardianship or imprisonment)
Key Trial Info
Start Date :
April 7 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT07010939
Start Date
April 7 2025
End Date
December 31 2028
Last Update
September 12 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China, 100021
2
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
Shenzhen, Guangdong, China, 518116
3
Shanxi Cancer Hospital
Taiyuan, Shanxi, China, 030013